Gartner Blog Network

New Research: Market Guide for CRM in Pharma and Biotech

by Stephen Davies  |  March 28, 2016  |  Submit a Comment

Recently, Gartner published the latest Market Guide for CRM in Pharma and Biotech. This is the second version of this guide focused on defining the CRM market in Pharma and Biotech and profiling vendors in the space.

A number of vendors were added and dropped during this market guide update process. Updated vendor profiles, market definition and direction reflects the latest information based on Gartner research and analysis. Key areas of focus for this update are; impact of IMS Health acquisition of Cegedim CRM assets, growth of Veeva market share and the continued march towards digital multichannel engagement.

Contact me to discuss the latest updates to the market guide and explore the impact on your organization.


Additional Resources

View Free, Relevant Gartner Research

Gartner's research helps you cut through the complexity and deliver the knowledge you need to make the right decisions quickly, and with confidence.

Read Free Gartner Research

Category: crm  multichannel-marketing  new-research  pharma-biotech  

Tags: biotech  cio  crm  market-guide  multichannel  pharma  pharmaceutical  

Stephen Davies
Research Director
4 years at Gartner
32 years IT Industry

Stephen Davies is a member of the Healthcare team within the Industries Research organization. He covers the technology aspects of commercialization topics (CRM, revenue management, contract management, compliance) for the life sciences area. Read Full Bio

Leave a Reply

Your email address will not be published. Required fields are marked *

Comments or opinions expressed on this blog are those of the individual contributors only, and do not necessarily represent the views of Gartner, Inc. or its management. Readers may copy and redistribute blog postings on other blogs, or otherwise for private, non-commercial or journalistic purposes, with attribution to Gartner. This content may not be used for any other purposes in any other formats or media. The content on this blog is provided on an "as-is" basis. Gartner shall not be liable for any damages whatsoever arising out of the content or use of this blog.